We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $499M
1-Year Est. Return 186.05%
This Fund
S&P 500
This Quarter Est. Return
+20.24%
1 Year Est. Return
+186.05%
3 Year Est. Return
+672.09%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$290M
AUM Growth
+$19.5M
Cap. Flow
+$9.29M
Cap. Flow %
3.2%
Top 10 Hldgs %
66.21%
Holding
46
New
10
Increased
7
Reduced
4
Closed
12

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$9.95M
2
APLS
Apellis Pharmaceuticals
APLS
+$8.88M
3
ETNB
89bio
ETNB
+$8.17M
4
VKTX icon
Viking Therapeutics
VKTX
+$6.6M
5
AZN icon
AstraZeneca
AZN
+$6.51M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$16.1M
2
BIIB icon
Biogen
BIIB
+$8.25M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$5.64M
4
LLY icon
Eli Lilly
LLY
+$4.5M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.76M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
26
Vaxcyte
PCVX
$7.81B
$1.93M 0.66%
38,555
+15,796
+69% +$749K
CBAY
27
DELISTED
Cymabay Therapeutics
CBAY
$1.85M 0.64%
169,277
– –
PLRX icon
28
Pliant Therapeutics
PLRX
$64.4M
$1.81M 0.62%
+100,000
New +$2.37M
CRL icon
29
Charles River Laboratories
CRL
$11.2B
$1.45M 0.5%
6,905
– –
TYRA icon
30
Tyra Biosciences
TYRA
$1.9B
$771K 0.27%
45,253
– –
WAT icon
31
Waters Corp
WAT
$37B
$758K 0.26%
2,845
– –
BMEA icon
32
Biomea Fusion
BMEA
$84.6M
$559K 0.19%
+25,452
New +$797K
MOR
33
DELISTED
MorphoSys AG American Depositary Shares
MOR
$325K 0.11%
+43,499
New +$265K
GRTS
34
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$186K 0.06%
+95,170
New +$223K
ALT icon
35
CALL
Altimmune
ALT
$552M
– –
-100,000
Closed -$422K
AMLX icon
36
Amylyx Pharmaceuticals
AMLX
$2.26B
– –
-8,339
Closed -$245K
AMRN
37
Amarin Corp
AMRN
$299M
– –
-12,840
Closed -$385K
KYNB
38
Kyntra Bio
KYNB
$27.2M
– –
-2,072
Closed -$966K
LEGN icon
39
Legend Biotech
LEGN
$3.59B
– –
-5,000
Closed -$241K
LRMR icon
40
Larimar Therapeutics
LRMR
$397M
– –
-38,057
Closed -$172K
NVO
41
CALL
Novo Nordisk
NVO
$208B
– –
-100,000
Closed -$7.96M
SRPT icon
42
CALL
Sarepta Therapeutics
SRPT
$1.57B
– –
-60,000
Closed -$8.27M
VRNA
43
DELISTED
Verona Pharma
VRNA
– –
-90,451
Closed -$1.82M
KRTX
44
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-88,831
Closed -$16.1M
KRTX
45
PUT
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-30,000
Closed -$5.45M
RETA
46
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-40,000
Closed -$3.64M
1
2

Similar funds

MIP
Marietta Investment Partners Milwaukee, Wisconsin $499M AUM 41.06% 1-Year Est. Return
H2CM
H/2 Credit Manager Stamford, Connecticut $500M AUM 24.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
KCL
KR Capital LP New York City, New York $499M AUM
PPC
Park Place Capital Homewood, Alabama $499M AUM 14.38% 1-Year Est. Return
HIC
Holderness Investments Company Greensboro, North Carolina $498M AUM 34.39% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $498M AUM 20.41% 1-Year Est. Return

Artia Global Partners's Q2 2023 Portfolio in Review

As of Q2 2023, Artia Global Partners held 46 positions worth $290M, up 7.2% from $271M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Artia Global Partners deployed $9.29M of net new capital in Q2 2023, opening 10 new positions and adding to 7 existing holdings. Its largest new stake was Sarepta Therapeutics: 77,162 shares worth $8.84M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was Biogen, an estimated $8.25M trimmed.

  • Artia Global Partners's largest Q2 2023 buy was Sarepta Therapeutics: 77,162 shares worth $8.84M.
  • Artia Global Partners added most to Viking Therapeutics in Q2 2023, an estimated $6.6M increase.
  • Artia Global Partners's biggest Q2 2023 reduction was Biogen, cutting an estimated $8.25M.
  • Artia Global Partners fully exited Karuna Therapeutics, Inc. Common Stock in Q2 2023, selling an estimated $16.1M.
  • Artia Global Partners's ten largest holdings make up 66% of its $290M portfolio in Q2 2023.
  • Artia Global Partners opened 10 new positions and closed 12 in Q2 2023.
  • Artia Global Partners's portfolio value rose 7.2% quarter-over-quarter to $290M.

Based on Artia Global Partners's 13F filing for Q2 2023, filed 14 Aug 2023.